ARTICLE | Financial News
Hua Medicine planning Hong Kong IPO
June 6, 2018 3:20 PM UTC
Diabetes company Hua Medicine Ltd. (Shanghai, China) filed for an IPO on the Hong Kong stock exchange underwritten by Goldman Sachs and CLSA Capital Markets.
Hua is the second biotech company to file for a Hong Kong listing since Hong Kong Exchanges and Clearing Ltd. (HKEX) opened a new prerevenue biotech chapter on April 30. Antiviral play Ascletis Pharma Inc. (Hangzhou, China) is also planning a listing, with Goldman Sachs among its underwriters (see BioCentury Extra, May 7)...